Luo et al. also discovered that the lncRNAs implicated in dasatinib resistance predominantly modulate metabolic pathways, with the main lncRNA MALAT1 associated with a favorable outcome in CML [131]. The gene discussed is MALAT1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.